(ARVN) Arvinas - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 586m USD | Total Return: 34.5% in 12m

Protein Degraders, Cancer Therapies, Neurological Treatments
Total Rating 20
Safety 17
Buy Signal -0.23
Biotechnology
Industry Rotation: -15.9
Market Cap: 586M
Avg Turnover: 7.79M
Risk 3d forecast
Volatility60.3%
VaR 5th Pctl9.61%
VaR vs Median-3.32%
Reward TTM
Sharpe Ratio0.74
Rel. Str. IBD24.1
Rel. Str. Peer Group33.1
Character TTM
Beta1.487
Beta Downside2.483
Hurst Exponent0.484
Drawdowns 3y
Max DD88.40%
CAGR/Max DD-0.33
CAGR/Mean DD-0.53
EPS (Earnings per Share) EPS (Earnings per Share) of ARVN over the last years for every Quarter: "2021-03": -0.84, "2021-06": -1.03, "2021-09": -0.94, "2021-12": -1, "2022-03": -1.2, "2022-06": -1.32, "2022-09": -1.24, "2022-12": -1.56, "2023-03": -1.54, "2023-06": -1.25, "2023-09": -1.18, "2023-12": -2.53, "2024-03": -0.97, "2024-06": -0.49, "2024-09": -0.68, "2024-12": -0.63, "2025-03": 1.14, "2025-06": -0.84, "2025-09": -0.48, "2025-12": -1.1, "2026-03": -0.9,
EPS CAGR: 7.63%
EPS Trend: 46.4%
Last SUE: 0.08
Qual. Beats: 0
Revenue Revenue of ARVN over the last years for every Quarter: 2021-03: 5.5, 2021-06: 5.5, 2021-09: 9.3, 2021-12: 26.3, 2022-03: 26.5, 2022-06: 33.8, 2022-09: 33.2, 2022-12: 38, 2023-03: 32.5, 2023-06: 54.5, 2023-09: 34.6, 2023-12: -43.1, 2024-03: 25.3, 2024-06: 76.5, 2024-09: 102.4, 2024-12: 59.2, 2025-03: 188.8, 2025-06: 22.4, 2025-09: 41.9, 2025-12: 9.5, 2026-03: 15.6,
Rev. CAGR: -18.63%
Rev. Trend: 3.5%
Last SUE: -0.02
Qual. Beats: 0

Warnings

Beneish M-Score -1.28 > -1.5 - likely earnings manipulation

Altman Z'' -11.85 < 1.0 - financial distress zone

Tailwinds

Confidence

Description: ARVN Arvinas

Arvinas, Inc. is a clinical-stage biotechnology firm specializing in the development of proteolysis targeting chimeras (PROTAC). This therapeutic approach utilizes the body’s ubiquitin-proteasome system to selectively degrade and remove pathogenic proteins rather than merely inhibiting them. The company’s pipeline targets high-prevalence conditions, including metastatic breast cancer, prostate cancer, and neurodegenerative disorders such as Parkinson’s disease.

The biotechnology sector often relies on strategic partnerships to fund capital-intensive clinical trials and leverage global distribution networks. Arvinas maintains active collaborations with major pharmaceutical entities, including Pfizer, Genentech, and Bayer, to advance its protein degradation platform. Unlike traditional small-molecule inhibitors that require high occupancy of a proteins active site, PROTAC degraders act catalytically, potentially allowing for lower dosing and reduced systemic toxicity.

To better understand how these clinical milestones might impact long-term valuation, you may wish to review the detailed financial metrics available on ValueRay. Arvinas continues to focus on its lead candidates, vepdegestrant and bavdegalutamide, as it transitions through various phases of human clinical testing.

Headlines to Watch Out For
  • Vepdegestrant phase 3 clinical data readouts determine long-term commercial viability in breast cancer
  • Strategic collaboration milestones and royalty payments from Pfizer drive near-term cash runway
  • Clinical trial progression of PROTAC platform candidates impacts valuation of protein degradation technology
  • Regulatory approval hurdles for novel degrader mechanisms influence investor risk appetite and sentiment
Piotroski VR‑10 (Strict) 1.0
Net Income: -221.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.40 > 0.02 and ΔFCF/TA -14.42 > 1.0
NWC/Revenue: 575.8% < 20% (prev 179.4%; Δ 396.5% < -1%)
CFO/TA -0.39 > 3% & CFO -254.1m > Net Income -221.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.44 > 1.5 & < 3
Outstanding Shares: last quarter (64.0m) vs 12m ago -11.97% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 10.85% > 50% (prev 42.64%; Δ -31.80% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -11.85
A: 0.80 (Total Current Assets 630.7m - Total Current Liabilities 115.9m) / Total Assets 647.5m
B: -2.58 (Retained Earnings -1.67b / Total Assets 647.5m)
C: -0.29 (EBIT TTM -236.2m / Avg Total Assets 824.3m)
D: -6.41 (Book Value of Equity -1.67b / Total Liabilities 260.7m)
Altman-Z'' Score: -11.85 = D
Beneish M -1.28
DSRI: 3.64 (Receivables 6.40m/8.40m, Revenue 89.4m/426.9m)
GMI: 1.02 (GM 97.43% / 99.23%)
AQI: 1.13 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 0.21 (Revenue 89.4m / 426.9m)
TATA: 0.05 (NI -221.3m - CFO -254.1m) / TA 647.5m)
Beneish M-Score: -1.28 (Cap -4..+1) = D
What is the price of ARVN shares? As of May 19, 2026, the stock is trading at USD 8.78 with a total of 954,742 shares traded.
Over the past week, the price has changed by -9.11%, over one month by -18.78%, over three months by -25.72% and over the past year by +34.46%.
Is ARVN a buy, sell or hold? Arvinas has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ARVN.
  • StrongBuy: 9
  • Buy: 4
  • Hold: 8
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ARVN price?
Analysts Target Price 15 70.8%
Arvinas (ARVN) - Fundamental Data Overview as of 18 May 2026
P/E Forward = 17.8571
P/S = 6.5532
P/B = 1.5021
Revenue TTM = 89.4m USD
EBIT TTM = -236.2m USD
EBITDA TTM = -231.7m USD
Long Term Debt = 400k USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 8.60m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -606.3m USD (recalculated: Debt 8.60m - CCE 614.9m)
Enterprise Value = 585.9m USD (floored to Market Cap, CCE > MCap+Debt)
 Interest Coverage Ratio = unknown (Ebit TTM -236.2m / Interest Expense TTM 0.0)
 EV/FCF = -2.28x (Enterprise Value 585.9m / FCF TTM -256.9m)
FCF Yield = -43.85% (FCF TTM -256.9m / Enterprise Value 585.9m)
 FCF Margin = -287.4% (FCF TTM -256.9m / Revenue TTM 89.4m)
 Net Margin = -247.5% (Net Income TTM -221.3m / Revenue TTM 89.4m)
 Gross Margin = unknown ((Revenue TTM 89.4m - Cost of Revenue TTM 2.30m) / Revenue TTM)
 Tobins Q-Ratio = 0.90 (Enterprise Value 585.9m / Total Assets 647.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.60m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.6m (EBIT -236.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.44 (Total Current Assets 630.7m / Total Current Liabilities 115.9m)
Debt / Equity = 0.02 (Debt 8.60m / totalStockholderEquity, last quarter 386.8m)
 Debt / EBITDA = 2.62 (negative EBITDA) (Net Debt -606.3m / EBITDA -231.7m)
 Debt / FCF = 2.36 (negative FCF - burning cash) (Net Debt -606.3m / FCF TTM -256.9m)
 Total Stockholder Equity = 498.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.85% (Net Income -221.3m / Total Assets 647.5m)
RoE = -44.39% (Net Income TTM -221.3m / Total Stockholder Equity 498.6m)
RoCE = -47.34% (EBIT -236.2m / Capital Employed (Equity 498.6m + L.T.Debt 400k))
 RoIC = -34.80% (negative operating profit) (NOPAT -186.6m / Invested Capital 536.3m)
 WACC = 11.05% (E(585.9m)/V(594.5m) * Re(11.21%) + D(8.60m)/V(594.5m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.97 | Cagr: 2.08%
 [DCF] Fair Price = unknown (Cash Flow -256.9m)
 EPS Correlation: 46.43 | EPS CAGR: 7.63% | SUE: 0.08 | # QB: 0
Revenue Correlation: 3.55 | Revenue CAGR: -18.63% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=+50.15% | Revisions=N/A | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=+13.65% | Revisions=+20% | Analysts=15
EPS current Year (2026-12-31): EPS=-2.90 | Chg30d=+17.40% | Revisions=+33% | GrowthEPS=-154.1% | GrowthRev=-53.4%
EPS next Year (2027-12-31): EPS=-3.33 | Chg30d=+5.52% | Revisions=-20% | GrowthEPS=-14.9% | GrowthRev=-39.1%
[Analyst] Revisions Ratio: +33%